Physician profile
Nilay Nahar
NPI 1114992153
$663.66
in general payments reported to CMS, 2019-2025
9 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.33 · 2022: $151 · 2023: $102 · 2024: $24.61 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.45 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $310.68 | 2025 | Venovo, Wavelinq |
| Horizon Therapeutics Plc | $128.59 | 2022 | |
| Calliditas Therapeutics US INC. | $102.00 | 2023 | Tarpeyo |
| Nxstage Medical, INC. | $46.33 | 2020 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Integra Lifesciences Corporation | $22.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.59 | 2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.18 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $0.39 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilay Nahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.